PMCB revenueQ1 2027$0
PMCB revenue was $0 in fiscal Q1 2027 (ended Jul 31, 2026), compared with $0 a year earlier. For the full fiscal 2026 it was $0, compared with $0 in fiscal 2025.
PharmaCyte Biotech Inc. (PMCB) financials
For the twelve months ended Jul 31, 2026, PharmaCyte Biotech Inc. reported $0 of revenue and -$16.15M of net income.
- Revenue, TTM
- $0
- Net income, TTM
- -$16.15M
- Cash
- $17.74M
- Market cap
- $3.8M
FY2017FY2026
FY2017FY2026
PMCB revenue and earnings growth
PMCB net incomeQ1 2027-$5.08M
PMCB net income was -$5.08M in fiscal Q1 2027 (ended Jul 31, 2026), compared with -$8.36M a year earlier. For the full fiscal 2026 it was -$19.42M, compared with $30.66M in fiscal 2025.
PMCB EPSQ1 2027-$0.54
PMCB diluted EPS was -$0.54 in fiscal Q1 2027 (ended Jul 31, 2026). For the full fiscal 2026 it was -$2.77, compared with $3.19 in fiscal 2025.
Income statement
| Line item | Apr 30, 2026 | Apr 30, 2025 | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 | Apr 30, 2021 | Apr 30, 2020 | Apr 30, 2019 | Apr 30, 2018 | Apr 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $391.3K | $438.4K | $407.4K | $468.5K | $690.9K | $916.2K | $301.2K | $460.1K | $2.00M | $1.18M |
| Selling, general and admin | $4.91M | $3.94M | $6.11M | $1.11M | $1.09M | $418.1K | $1.16M | $1.38M | $1.82M | $744.8K |
| Operating income | -$6.85M | -$4.38M | -$8.52M | -$6.46M | -$4.39M | -$3.62M | -$3.83M | -$4.10M | -$6.98M | -$4.44M |
| Interest expense | - | - | - | $0 | $509 | $3.0K | $453 | $0 | $0 | $1.5K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19.42M | $30.66M | $333.8K | -$4.32M | -$4.24M | -$3.55M | -$3.83M | -$4.07M | -$6.83M | -$4.44M |
| EPS, basic | -$2.77 | $3.19 | -$1.80 | -$0.22 | -$0.27 | -$2.45 | -$4.23 | $0.00 | -$0.01 | -$0.01 |
| EPS, diluted | -$2.77 | $3.19 | -$1.80 | -$0.22 | -$0.27 | -$2.45 | -$4.23 | $0.00 | -$0.01 | -$0.01 |
| Diluted shares | 8.4M | 7.3M | 9.6M | 19.5M | 15.5M | 1.4M | 903,812 | 1.10B | 968.6M | 845.3M |
Balance sheet
| Line item | Apr 30, 2026 | Apr 30, 2025 | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 | Apr 30, 2021 | Apr 30, 2020 | Apr 30, 2019 | Apr 30, 2018 | Apr 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $18.60M | $15.17M | $50.18M | $68.04M | $85.40M | $2.20M | $894.9K | $515.3K | $1.06M | $3.46M |
| Short-term investments | $254.0K | $366.3K | $0 | - | - | - | - | - | - | - |
| Current assets | $37.42M | $22.38M | $50.44M | $68.15M | $85.49M | $2.28M | $1.04M | $653.4K | $1.28M | $3.54M |
| Total assets | $46.75M | $55.17M | $59.90M | $73.28M | $90.62M | $7.40M | $6.17M | $5.78M | $6.41M | $8.67M |
| Current liabilities | $826.4K | $2.91M | $7.42M | $586.6K | $704.4K | $724.8K | $1.03M | $742.9K | $644.2K | $580.2K |
| Total liabilities | $11.77M | $3.28M | $20.39M | $586.6K | $704.4K | $724.8K | $1.08M | $742.9K | $644.2K | $580.2K |
| Shareholders' equity | $33.29M | $51.89M | $27.65M | $72.69M | $89.92M | $6.68M | $5.09M | $5.04M | $5.77M | $8.09M |
Cash flow
| Line item | Apr 30, 2026 | Apr 30, 2025 | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 | Apr 30, 2021 | Apr 30, 2020 | Apr 30, 2019 | Apr 30, 2018 | Apr 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.15M | -$2.98M | -$2.15M | -$3.79M | -$4.12M | -$3.33M | -$2.34M | -$2.88M | -$5.08M | -$3.34M |
| Investing cash flow | $2.00M | -$7.00M | -$5.00M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $6.58M | -$25.03M | -$10.71M | -$13.56M | $87.31M | $4.64M | $2.73M | $2.34M | $2.68M | $4.88M |
| Share repurchases | $401.6K | $2.54M | $28.20M | $13.56M | $0 | - | - | - | - | - |
| Stock-based compensation | $892.5K | $0 | $674.7K | $7.3K | $33.1K | $194.3K | $368.6K | $293.3K | $580.4K | $420.5K |
Key ratios
| Line item | Apr 30, 2026 | Apr 30, 2025 | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 | Apr 30, 2021 | Apr 30, 2020 | Apr 30, 2019 | Apr 30, 2018 | Apr 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income growth, YoY | - | 9085.0% | - | - | - | - | - | - | - | - |
| Return on equity | -58.3% | 59.1% | 1.2% | -5.9% | -4.7% | -53.2% | -75.2% | -80.7% | -118.4% | -54.9% |
| Return on assets | -41.5% | 55.6% | 0.6% | -5.9% | -4.7% | -48.0% | -62.1% | -70.3% | -106.5% | -51.3% |
| Current ratio | 45.28 | 7.68 | 6.80 | 116.18 | 121.38 | 3.14 | 1.01 | 0.88 | 1.99 | 6.10 |
Income statement
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $60.0K | $61.9K | $93.1K | $141.1K | $95.2K | $126.7K | $118.2K | $97.5K | $96.0K | $94.2K | $126.7K | $82.0K |
| Selling, general and admin | $946.7K | $899.9K | $2.02M | $1.23M | $753.1K | $915.1K | $842.1K | $1.01M | $1.17M | $4.23M | $251.9K | $272.5K |
| Operating income | -$1.01M | -$2.51M | -$2.12M | -$1.38M | -$848.3K | -$1.04M | -$960.3K | -$1.11M | -$1.27M | -$3.17M | -$1.87M | -$1.41M |
| Income tax | $0 | - | - | - | $0 | - | - | - | - | - | - | - |
| Net income | -$5.08M | -$4.39M | $746.9K | -$7.42M | -$8.36M | $11.75M | -$3.05M | -$1.47M | $23.42M | $1.35M | -$619.5K | $2.79M |
| EPS, basic | -$0.54 | - | -$0.17 | -$1.24 | -$1.23 | $2.12 | -$0.44 | -$0.39 | $1.90 | - | -$0.65 | -$0.26 |
| EPS, diluted | -$0.54 | - | -$0.17 | -$1.24 | -$1.23 | $2.12 | -$0.44 | -$0.39 | $1.90 | - | -$0.65 | -$0.26 |
| Diluted shares | 10.7M | - | 9.3M | 6.8M | 6.8M | - | 7.0M | 7.6M | 7.9M | - | 8.6M | 8.8M |
Balance sheet
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $17.74M | $18.60M | $20.17M | $15.41M | $13.18M | $15.17M | $16.38M | $20.84M | $32.64M | $50.18M | $61.21M | $73.43M |
| Short-term investments | $99.5K | $254.0K | $372.3K | $201.2K | $261.9K | $366.3K | $372.6K | - | - | $0 | - | - |
| Current assets | $30.97M | $37.42M | $20.70M | $23.02M | $19.11M | $22.38M | $16.96M | $21.33M | $32.88M | $50.44M | $61.51M | $73.75M |
| Total assets | $36.71M | $46.75M | $55.87M | $55.98M | $45.11M | $55.17M | $43.83M | $55.10M | $70.19M | $59.90M | $71.36M | $78.88M |
| Current liabilities | $768.7K | $826.4K | $1.68M | $1.58M | $1.06M | $2.91M | $1.19M | $4.78M | $7.47M | $7.42M | $7.54M | $5.24M |
| Total liabilities | $6.90M | $11.77M | $16.47M | $19.42M | $1.52M | $3.28M | $3.58M | $11.65M | $17.15M | $20.39M | $22.47M | $20.81M |
| Shareholders' equity | $27.51M | $33.29M | $38.11M | $35.24M | $43.59M | $51.89M | $40.25M | $43.45M | $47.71M | $27.65M | $31.37M | $36.77M |
Cash flow
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$780.9K | -$1.39M | -$786.8K | -$979.5K | -$1.99M | -$1.04M | -$509.9K | -$1.05M | -$373.3K | -$333.0K | -$177.1K | -$1.98M |
| Investing cash flow | - | $0 | $5.00M | -$3.00M | $0 | $0 | $0 | $0 | -$7.00M | $0 | -$5.00M | $0 |
| Financing cash flow | -$83.4K | -$169.8K | $543.8K | $6.21M | $0 | -$171.5K | -$3.95M | -$10.74M | -$10.17M | -$10.70M | -$7.04M | $748.7K |
| Share repurchases | - | $0 | $401.6K | $0 | $0 | $171.5K | $225.0K | $1.40M | $742.2K | $1.17M | $404.7K | $165.0K |
| Stock-based compensation | - | $0 | $771.5K | $60.5K | $60.5K | $0 | -$341.8K | $119.2K | $222.7K | $0 | $674.7K | $0 |
Key ratios
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income growth, YoY | - | - | - | - | - | 772.5% | - | - | - | - | - | - |
| Current ratio | 40.30 | 45.28 | 12.33 | 14.60 | 18.01 | 7.68 | 14.20 | 4.47 | 4.40 | 6.80 | 8.16 | 14.08 |
Source: XBRL data PharmaCyte Biotech Inc. files with the SEC, latest filing dated Sep 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PMCB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PMCB | $0 | - | -$16.15M | - | $3.8M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
PMCB FAQ
5 questionsWhat is PMCB revenue?
PharmaCyte Biotech Inc. (PMCB) reported $0 of revenue for the twelve months ended Jul 31, 2026. Revenue for fiscal 2026 was $0.Is PMCB profitable?
No. PharmaCyte Biotech Inc. reported a net loss of $16.15M for the twelve months ended Jul 31, 2026.How much cash and debt does PMCB have?
PharmaCyte Biotech Inc. reported $17.74M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did PMCB last report financial results?
The latest statements here come from PharmaCyte Biotech Inc.'s 10-Q filed on Sep 14, 2026, covering the period ended Jul 31, 2026.Where does this PMCB financial data come from?
Quantisnow builds these statements from the structured XBRL data PharmaCyte Biotech Inc. files with the SEC. It is provided for information only and is not investment advice.